Skip to content
OpenCapital
Get started

Allogene Therapeutics ALLO Asset turnover

Asset turnover at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Gilead Sciences logo
Gilead SciencesGILD
0.5×0.0×
Precigen logo
PrecigenPGEN
0×—
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
0×0.0×
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
0.2×-0.9×
Janux Therapeutics logo
Janux TherapeuticsJANX
0×0.0×

Other financials

Income statement

See full
Revenue-—
Operating income-$46.1M+29.3%
Net income-$42.6M+28.7%
EPS (diluted)-$0.18+35.7%

Balance sheet

See full
Cash & equivalents$40.6M-23.0%
Total debt$81.1M-8.9%
Total equity$278.9M-27.6%
Total assets$396.0M-22.1%

Cash flow

See full
Operating cash flow-$12.9M+75.6%
CapEx$9.0K-90.9%
Free cash flow-$12.9M+75.6%

Valuation

See full
Market cap$711.02M+164%
Enterprise value$751.47M+146%

Profitability

See full
Operating margin-1,241,813.6%-2,018,140pp
Net margin-1,170,863.6%-2,007,890pp
FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full
Return on equity-52.3%-5.7pp
Debt / equity0.3×+0.1×
Current ratio9.6×-0.1×

Where this comes from

Calculated from Allogene Therapeutics’s reported figures.

total revenue/total assets=0×

Based on trailing twelve months.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Allogene Therapeutics's asset turnover?
Allogene Therapeutics (ALLO) reported asset turnover of 0× in Q4 2025.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.